At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 350 enrolled
Drug / intervention
Adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Adalimumab and ABP 501 for Psoriasis. Completed, enrolled 350 participants across 3 sites in 3 countries.
Detailed Summary
The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Canada, Hungary
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionAug 2014
Study CompletionMar 2015
TodayJul 2026
First PostedOct 28, 2013
Enrollment StartOct 18, 2013
Primary CompletionAug 14, 2014
Study CompletionMar 18, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.7 years ago
Interventions
Adalimumabbiological
Administered by subcutaneous injection
ABP 501biological
Administered by subcutaneous injection